351 related articles for article (PubMed ID: 10329815)
1. In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol.
Aziz I; Lipworth BJ
J Allergy Clin Immunol; 1999 May; 103(5 Pt 1):816-22. PubMed ID: 10329815
[TBL] [Abstract][Full Text] [Related]
2. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
Lipworth BJ; Aziz I
J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
[TBL] [Abstract][Full Text] [Related]
3. Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism.
Lipworth BJ; Dempsey OJ; Aziz I
Chest; 2000 Aug; 118(2):321-8. PubMed ID: 10936119
[TBL] [Abstract][Full Text] [Related]
4. Comparative trough effects of formoterol and salmeterol on lymphocyte beta2-adrenoceptor--regulation and bronchodilatation.
Aziz I; McFarlane LC; Lipworth BJ
Eur J Clin Pharmacol; 1999 Aug; 55(6):431-6. PubMed ID: 10492055
[TBL] [Abstract][Full Text] [Related]
5. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
6. Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol.
Grove A; Lipworth BJ
Thorax; 1996 Jun; 51(6):585-9. PubMed ID: 8693438
[TBL] [Abstract][Full Text] [Related]
7. The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol.
Lee DK; Currie GP; Hall IP; Lima JJ; Lipworth BJ
Br J Clin Pharmacol; 2004 Jan; 57(1):68-75. PubMed ID: 14678342
[TBL] [Abstract][Full Text] [Related]
8. Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting beta2-agonist therapy.
Lipworth BJ; Hall IP; Aziz I; Tan KS; Wheatley A
Clin Sci (Lond); 1999 Mar; 96(3):253-9. PubMed ID: 10029561
[TBL] [Abstract][Full Text] [Related]
9. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
Aziz I; Hall IP; McFarlane LC; Lipworth BJ
J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
[TBL] [Abstract][Full Text] [Related]
10. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction.
Politiek MJ; Boorsma M; Aalbers R
Eur Respir J; 1999 May; 13(5):988-92. PubMed ID: 10414394
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol.
Grove A; Lipworth BJ
Thorax; 1996 Jan; 51(1):54-8. PubMed ID: 8658370
[TBL] [Abstract][Full Text] [Related]
12. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study.
Cazzola M; Matera MG; Santangelo G; Vinciguerra A; Rossi F; D'Amato G
Respir Med; 1995 May; 89(5):357-62. PubMed ID: 7638371
[TBL] [Abstract][Full Text] [Related]
13. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
[TBL] [Abstract][Full Text] [Related]
14. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.
Kalra S; Swystun VA; Bhagat R; Cockcroft DW
Chest; 1996 Apr; 109(4):953-6. PubMed ID: 8635376
[TBL] [Abstract][Full Text] [Related]
15. Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi.
Molimard M; Naline E; Zhang Y; Le Gros V; Begaud B; Advenier C
Eur Respir J; 1998 Mar; 11(3):583-8. PubMed ID: 9596106
[TBL] [Abstract][Full Text] [Related]
16. Effects of genetic polymorphism on ex vivo and in vivo function of beta2-adrenoceptors in asthmatic patients.
Lipworth BJ; Hall IP; Tan S; Aziz I; Coutie W
Chest; 1999 Feb; 115(2):324-8. PubMed ID: 10027427
[TBL] [Abstract][Full Text] [Related]
17. Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype.
Lipworth BJ; Dempsey OJ; Aziz I; Wilson AM
Am J Med; 2000 Aug; 109(2):114-21. PubMed ID: 10967152
[TBL] [Abstract][Full Text] [Related]
18. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
Wechsler ME; Kunselman SJ; Chinchilli VM; Bleecker E; Boushey HA; Calhoun WJ; Ameredes BT; Castro M; Craig TJ; Denlinger L; Fahy JV; Jarjour N; Kazani S; Kim S; Kraft M; Lazarus SC; Lemanske RF; Markezich A; Martin RJ; Permaul P; Peters SP; Ramsdell J; Sorkness CA; Sutherland ER; Szefler SJ; Walter MJ; Wasserman SI; Israel E;
Lancet; 2009 Nov; 374(9703):1754-64. PubMed ID: 19932356
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients.
Palmqvist M; Ibsen T; Mellén A; Lötvall J
Am J Respir Crit Care Med; 1999 Jul; 160(1):244-9. PubMed ID: 10390407
[TBL] [Abstract][Full Text] [Related]
20. Salmeterol does not alter increased bronchial responsiveness caused by organic dust exposure.
Ek A; Palmberg L; Sundblad BM; Larsson K
Chest; 2005 Oct; 128(4):3038-47. PubMed ID: 16236984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
